Helperby Therapeutics Ltd (Helperby) has collaborated with Dr. Pamela Yeh and her team at the Department of Ecology and Evolutionary Biology, University of California, Los Angeles (UCLA).
Both organizations concentrate on the use of antibiotics in combinations to target antimicrobial resistant bacteria which are rapidly threatening the efficacy of existing antibiotic therapies. The World Health Organization recognizes antimicrobial resistance as one of the most pressing global threats to health.
It was previously held that the risks of combining antibiotic drugs often outweighed the benefit because of adverse interactions. But Dr Yeh's team found the direct opposite, and reported that as more drugs were combined, an elevated frequency of synergy was observed1.
Helperby and Dr Yeh's team will work closely to explore the commercial opportunity of additional, new, combination therapies. The collaboration will include the sharing of data, expertise and research methodology.
Helperby recently presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) announcing Phase I results on the tolerability, pharmacokinetics and pharmacodynamics of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.
Helperby also presented...